A novel strategy for circumventing safety problems that have plagued gene therapy has been offered by a complex multicenter group of researchers.
The study reports that adenovirus type 5, a common vector for delivering gene therapy, transfects liver cells by a different mechanism than previously thought.
That mechanism offers a new target for modifying the viral vector to make it safe for clinical use.
...
Post new comment